{"filing":{"accession_number":"0001279569-26-000905","cik":"0001702123","ticker":"CRDL","company_name":"Cardiol Therapeutics Inc.","form":"6-K","filing_date":"2026-09-23","report_date":"2026-09-23","primary_document":"cardiol6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1702123/000127956926000905/cardiol6k.htm"},"events":[{"id":34458,"run_id":31703,"accession_number":"0001279569-26-000905","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This news release announces a material clinical trial milestone: achievement of the Phase III MAVERIC enrollment target (110 patients) ahead of schedule, coupled with a planned expansion to 150 patients based on a blinded review showing fewer-than-expected recurrences. The disclosure includes revised topline results guidance (mid-2027 vs. Q1 2027) and cash runway extension to Q1 2028. While this is an operational/clinical development event rather than a discrete financial event (earnings, debt, M\u0026A, or litigation), it materially affects investor assessment of the registrant's lead program progress and capital adequacy for a late-stage biotech company.","company_name":"Cardiol Therapeutics Inc.","ticker":"CRDL","filing_date":"2026-09-23","form":"6-K","submitted_at":null,"items":[{"id":38182,"accession_number":"0001279569-26-000905","item_number":"EX-99.1","item_title":"ex991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This news release announces a material clinical trial milestone: achievement of the Phase III MAVERIC enrollment target (110 patients) ahead of schedule, coupled with a planned expansion to 150 patients based on a blinded review showing fewer-than-expected recurrences. The disclosure includes revised topline results guidance (mid-2027 vs. Q1 2027) and cash runway extension to Q1 2028. While this is an operational/clinical development event rather than a discrete financial event (earnings, debt, M\u0026A, or litigation), it materially affects investor assessment of the registrant's lead program progress and capital adequacy for a late-stage biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-23T10:39:43.685198+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38182,"accession_number":"0001279569-26-000905","item_number":"EX-99.1","item_title":"ex991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This news release announces a material clinical trial milestone: achievement of the Phase III MAVERIC enrollment target (110 patients) ahead of schedule, coupled with a planned expansion to 150 patients based on a blinded review showing fewer-than-expected recurrences. The disclosure includes revised topline results guidance (mid-2027 vs. Q1 2027) and cash runway extension to Q1 2028. While this is an operational/clinical development event rather than a discrete financial event (earnings, debt, M\u0026A, or litigation), it materially affects investor assessment of the registrant's lead program progress and capital adequacy for a late-stage biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-23T10:39:43.685198+00:00","company_name":"Cardiol Therapeutics Inc.","ticker":"CRDL","filing_date":"2026-09-23"}]}